X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
INP105 (olanzapine) is being developed as an acute treatment for agitation in persons with autism spectrum disorder (ASD) using Impel’s proprietary Precision Olfactory Delivery (POD®) technology which delivers drugs to the upper nasal space.
Lead Product(s): Olanzapine
Therapeutic Area: Neurology Product Name: INP105
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022
Details:
Trudhesa (Dihydroergotamine Mesylate), is a single use, drug-device combination product containing a vial of DHE, gently delivers DHE—a proven, well-established therapeutic6—quickly to the bloodstream through the vascular-rich upper nasal space.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: Trudhesa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
This non-dilutive financing provides Impel with immediate and sufficient capital to support the continued successful launch and commercialization efforts for Trudhesa.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: Trudhesa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oaktree Capital
Deal Size: $50.0 million Upfront Cash: $50.0 million
Deal Type: Financing March 17, 2022
Details:
Using Impel’s proprietary POD® technology, Trudhesa delivers dihydroergotamine mesylate (DHE)—a proven, well-established therapeutic for acute migraine for adults—quickly to the bloodstream through the vascular-rich upper nasal space.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: Trudhesa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2022
Details:
In the trial, Trudhesa was generally well tolerated and exploratory efficacy findings showed it provided rapid, sustained, and consistent symptom relief.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: Trudhesa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
This strategic debt financing increases companies balance sheet strength and firmly positions us to execute upon the potential launch and commercialization of TRUDHESA™ for the treatment of patients with acute migraine.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: Trudhesa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oxford Finance LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing July 07, 2021
Details:
The NDA submission for INP104 is supported by safety results from the pivotal Phase 3 STOP 301 study, in which over 5,650 migraine attacks were treated over 24 or 52 weeks.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: INP104
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Within two hours of receiving their first dose of INP104, 38% of all patients reported freedom from migraine pain, 52% had freedom from their most bothersome migraine symptom (MBS) and 66.3% experienced pain relief.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: INP104
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
Study shows INP105 achieves rapid absorption which may provide an effective, convenient, & noninvasive future alternative for treating acute agitation in the home, community, or hospital setting.
Lead Product(s): Olanzapine
Therapeutic Area: Psychiatry/Psychology Product Name: INP105
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
Details:
Impel Neuropharma presented additional findings from pivotal Phase 3 STOP 301 study, which further illustrates INP104’s potential to become an important new option for patients in the treatment of acute migraine.
Lead Product(s): Dihydroergotamine Mesylate
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
